# Vaishali Sanchorawala

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5414261/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 253 papers | 9,725 citations | 50170 46 h-index | 42291 92 g-index |
| 256 all docs | 256 docs citations | 256 times ranked | 4451 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328. | 2.0 | 1,179 |
| 2 | High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. Annals of Internal Medicine, 2004, 140, 85. | 2.0 | 539 |
| 3 | Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38. | 18.1 | 350 |
| 4 | Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 2012, 26, 2317-2325. | 3.3 | 332 |
| 5 | Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood, 1998, 91, 3662-3670. | 0.6 | 323 |
| 6 | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58. | 13.9 | 268 |
| 7 | Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 2007, 109, 492-496. | 0.6 | 262 |
| 8 | Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352. | 0.6 | 259 |
| 9 | Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood, 2001, 97, 1885-1887. | 0.6 | 200 |
| 10 | Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1331-1341. | 2.2 | 191 |
| 11 | Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011, 118, 865-873. | 0.6 | 161 |
| 12 | Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica, 2013, 98, 141-146. | 1.7 | 155 |
| 13 | Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood, 2007, 110, 3561-3563. | 0.6 | 154 |
| 14 | Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, 114, 1489-1497. | 0.6 | 153 |
| 15 | An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 2001, 28, 637-642. | 1.3 | 149 |
| 16 | Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80. | 0.6 | 146 |
| 17 | Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chainâ€“Associated (AL) Amyloidosis. Clinical Lymphoma and Myeloma, 2003, 3, 241-246. | 2.1 | 137 |
| 18 | Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood, 2019, 133, 215-223. | 0.6 | 118 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood, 2016, 128, 1059-1062. | 0.6 | 117 |
| 20 | Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood, 2020, 135, 1541-1547. | 0.6 | 111 |
| 21 | Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosisâ€"Associated Renal Disease. Annals of Internal Medicine, 2001, 134, 746. | 2.0 | 111 |
| 22 | Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 2004, 104, 1888-1893. | 0.6 | 109 |
| 23 | Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood, 2015, 126, 2345-2347. | 0.6 | 109 |
| 24 | A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605. | 0.6 | 108 |
| 25 | Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67. | 1.4 | 108 |
| 26 | High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 2004, 33, 381-388. | 1.3 | 107 |
| 27 | Persistent Pleural Effusions in Primary Systemic Amyloidosis. Chest, 2003, 124, 969-977. | 0.4 | 106 |
| 28 | Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. Transplantation, 2010, 90, 905-911. | 0.5 | 103 |
| 29 | Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology Dialysis Transplantation, 2011, 26, 881-886. | 0.4 | 99 |
| 30 | Update on treatment of light chain amyloidosis. Haematologica, 2014, 99, 209-221. | 1.7 | 93 |
| 31 | Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 2005, 36, 597-600. | 1.3 | 92 |
| 32 | Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.. Blood, 2004, 104, 942-942. | 0.6 | 82 |
| 33 | Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986. | 3.3 | 73 |
| 34 | Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal of Haematology, 1999, 104, 553-559. | 1.2 | 68 |
| 35 | Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney International, 2003, 63, 1868-1873. | 2.6 | 63 |
| 36 | Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 339-343. | 1.3 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, 124, 2498-2506. | 0.6 | 62 |
| 38 | Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1057-1064. | 0.5 | 60 |
| 39 | High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney International, 2003, 63, 1051-1057. | 2.6 | 59 |
| 40 | Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood, 2010, 116, 5071-5072. | 0.6 | 59 |
| 41 | Long-term outcome of kidney transplantation in AL amyloidosis. Kidney International, 2019, 95, 405-411. | 2.6 | 57 |
| 42 | Spontaneous rupture of the spleen in AL amyloidosis. American Journal of Hematology, 2003, 74, 131-135. | 2.0 | 56 |
| 43 | Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1445-1451. | 2.0 | 55 |
| 44 | Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239. | 2.8 | 54 |
| 45 | Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10. | 2.8 | 53 |
| 46 | Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 2013, 98, 789-792. | 1.7 | 50 |
| 47 | Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2. | 1.4 | 49 |
| 48 | AL amyloidosis associated with B-cell lymphoproliferative disorders: Frequency and treatment outcomes. American Journal of Hematology, 2006, 81, 692-695. | 2.0 | 47 |
| 49 | Localized amyloidosis of the breast: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 72-75. | 1.4 | 47 |
| 50 | Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 2002, 117, 886-889. | 1.2 | 46 |
| 51 | Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 645-645. | 0.6 | 46 |
| 52 | Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal, 2021, 11, 139. | 2.8 | 45 |
| 53 | Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 210-215. | 1.4 | 44 |
| 54 | Myocardial infarction with â€œclean coronariesâ€•caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 160-164. | 1.4 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7. | 1.4 | 42 |
| 56 | Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplantation, 2014, 49, 434-439. | 1.3 | 41 |
| 57 | Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336. | 2.3 | 41 |
| 58 | Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 957-970. | 0.2 | 40 |
| 59 | Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Advances, 2020, 4, 880-884. | 2.5 | 40 |
| 60 | Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology, 2007, 82, 363-367. | 2.0 | 39 |
| 61 | High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood, 2012, 120, 4445-4446. | 0.6 | 38 |
| 62 | Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 2011, 96, 1890-1892. | 1.7 | 34 |
| 63 | Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139. | 0.6 | 34 |
| 64 | Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2005, 35, 567-575. | 1.3 | 33 |
| 65 | Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 2006, 108, 3945-3947. | 0.6 | 33 |
| 66 | Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplantation, 2007, 40, 557-562. | 1.3 | 33 |
| 67 | Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 2010, 116, 1990-1991. | 0.6 | 33 |
| 68 | Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology, 2020, 38, 1455-1462. | 0.8 | 31 |
| 69 | High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 127-132. | 2.0 | 31 |
| 70 | Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood, 2017, 130, 1383-1386. | 0.6 | 30 |
| 71 | An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 261-269. | 1.4 | 29 |
| 72 | A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235. | 3.3 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leukemia and Lymphoma, 2008, 49, 1108-1115. | 0.6 | 28 |
| 74 | Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 130-131. | 1.4 | 27 |
| 75 | A longitudinal evaluation of healthâ€related quality of life in patients with <scp>AL</scp> amyloidosis: associations with health outcomes over time. British Journal of Haematology, 2017, 179, 461-470. | 1.2 | 27 |
| 76 | Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 244-249. | 1.4 | 27 |
| 77 | Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166. | 0.6 | 27 |
| 78 | New Hematologic Response Criteria Predict Survival in Patients With Immunoglobulin Light Chain Amyloidosis Treated With High-Dose Melphalan and Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 2749-2750. | 0.8 | 26 |
| 79 | Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. European Journal of Haematology, 2020, 105, 495-501. | 1.1 | 26 |
| 80 | Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica, 2009, 94, 1029-1032. | 1.7 | 25 |
| 81 | Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Advances, 2019, 3, 216-218. | 2.5 | 25 |
| 82 | Establishment of brain natriuretic peptide â€•based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. British Journal of Haematology, 2020, 188, 424-427. | 1.2 | 25 |
| 83 | Lymphadenopathy as a manifestation of amyloidosis: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 256-260. | 1.4 | 24 |
| 84 | Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17. | 1.4 | 22 |
| 85 | Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal, 2020, 10, 118. | 2.8 | 21 |
| 86 | Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 2014, 124, 3450-3450. | 0.6 | 21 |
| 87 | Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 528-542. | 0.4 | 20 |
| 88 | Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplantation, 2013, 48, 1537-1542. | 1.3 | 20 |
| 89 | Macroglossia â€“ not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 83-86. | 1.4 | 19 |
| 90 | Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 229-235. | 1.4 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica, 2016, 101, 86-90. | 1.7 | 19 |
| 92 | High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Acta Haematologica, 2020, 143, 381-387. | 0.7 | 19 |
| 93 | A Case of Atypical Light Chain Deposition Diseaseâ€"Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 858-867. | 2.2 | 18 |
| 94 | Oral Cyclic Melphalan and Dexamethasone for Patients With AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 469-472. | 0.2 | 18 |
| 95 | Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 188-193. | 1.4 | 18 |
| 96 | Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 1-7. | 1.4 | 18 |
| 97 | Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia, 2021, 35, 916-919. | 3.3 | 18 |
| 98 | Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation, 2001, 28, 1105-1109. | 1.3 | 17 |
| 99 | Amyloidotic Cardiomyopathy: Multidisciplinary Approach to Diagnosis and Treatment. Heart Failure Clinics, 2011, 7, 385-393. | 1.0 | 17 |
| 100 | Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357. | 1.2 | 17 |
| 101 | Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 103-107. | 1.4 | 16 |
| 102 | High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Hematology/Oncology Clinics of North America, 2014, 28, 1131-1144. | 0.9 | 16 |
| 103 | Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2016, 91, E458-60. | 2.0 | 16 |
| 104 | Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Related Outcome Measures, 2017, Volume 8, 157-167. | 0.7 | 16 |
| 105 | Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 37-41. | 1.4 | 15 |
| 106 | Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. American Journal of Transplantation, 2019, 19, 3185-3190. | 2.6 | 15 |
| 107 | Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. Journal of Clinical Oncology, 2021, 39, 8003-8003. | 0.8 | 15 |
| 108 | A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2014, 124, 4741-4741. | 0.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology, 2010, 89, 579-584. | 0.8 | 14 |
| 110 | A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplantation, 2011, 46, 976-980. | 1.3 | 14 |
| 111 | A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196. | 1.4 | 14 |
| 112 | Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, e169-e173. | 2.0 | 14 |
| 113 | Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009. | 3.3 | 14 |
| 114 | Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer Journal, 2020, 10, 88. | 2.8 | 14 |
| 115 | Amyloid Deposits in the Bone Marrow of Patients with Immunoglobulin Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment. Biology of Blood and Marrow Transplantation, 2012, 18, 1935-1938. | 2.0 | 13 |
| 116 | The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplantation, 2017, 52, 1349-1351. | 1.3 | 13 |
| 117 | A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 148-155. | 1.4 | 13 |
| 118 | Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.. Journal of Clinical Oncology, 2010, 28, 8024-8024. | 0.8 | 13 |
| 119 | Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplantation, 2011, 46, 161-162. | 1.3 | 12 |
| 120 | The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1729-1732. | 2.0 | 12 |
| 121 | The six-minute walk test in patients with AL amyloidosis: a single centre case series. British Journal of Haematology, 2017, 177, 388-394. | 1.2 | 12 |
| 122 | Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 1823-1827. | 2.0 | 12 |
| 123 | Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 156-159. | 1.4 | 12 |
| 124 | Prevalence and prognostic value of Dâ€dimer elevation in patients with AL amyloidosis. American Journal of Hematology, 2019, 94, 1098-1103. | 2.0 | 12 |
| 125 | Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199. | 2.0 | 12 |
| 126 | Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 149-153. | 1.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Bortezomib ocular toxicities: Outcomes with ketotifen. American Journal of Hematology, 2019, 94, E80-E82. | 2.0 | 11 |
| 128 | The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney International Reports, 2020, 5, 485-493. | 0.4 | 11 |
| 129 | Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following StemÂCell Transplantation. JACC: CardioOncology, 2020, 2, 721-731. | 1.7 | 11 |
| 130 | Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50. | 0.6 | 11 |
| 131 | Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 156-160. | 1.4 | 10 |
| 132 | Once AL amyloidosis: not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 139-140. | 1.4 | 10 |
| 133 | Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2006, 108, 3094-3094. | 0.6 | 10 |
| 134 | Predictive factors of outcomes in patients with <scp>AL</scp> amyloidosis treated with daratumumab. American Journal of Hematology, 2022, 97, 79-89. | 2.0 | 10 |
| 135 | Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. HemaSphere, 2022, 6, e681. | 1.2 | 10 |
| 136 | Diaphragm paralysis in primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 193-196. | 1.4 | 9 |
| 137 | The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268. | 1.2 | 9 |
| 138 | Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 214-220. | 1.4 | 8 |
| 139 | <p>Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives</p>. Journal of Blood Medicine, 2019, Volume 10, 373-380. | 0.7 | 8 |
| 140 | The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 17-24. | 1.4 | 8 |
| 141 | Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study. Blood, 2018, 132, 2005-2005. | 0.6 | 8 |
| 142 | Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). Journal of Clinical Oncology, 2007, 25, 8050-8050. | 0.8 | 8 |
| 143 | Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 184-189. | 1.4 | 8 |
| 144 | Daratumumab in AL amyloidosis. Blood, 2022, 140, 2317-2322. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. American Journal of Hematology, 2020, 95, E45-E48. | 2.0 | 7 |
| 146 | Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1099-1113. | 0.9 | 7 |
| 147 | Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrology Dialysis Transplantation, 2022, 37, 1281-1288. | 0.4 | 7 |
| 148 | Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546. | 0.8 | 7 |
| 149 | Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2004, 104, 923-923. | 0.6 | 7 |
| 150 | High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 127-129. | 1.4 | 6 |
| 151 | A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 127-130. | 1.4 | 6 |
| 152 | Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplantation, 2014, 49, 1345-1346. | 1.3 | 6 |
| 153 | Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 124-127. | 1.4 | 6 |
| 154 | Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation, 2016, 51, 1318-1322. | 1.3 | 6 |
| 155 | Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2018, 93, E129-E132. | 2.0 | 6 |
| 156 | AL Amyloidosis in Myeloma: Red Flag Symptoms. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 777-778. | 0.2 | 6 |
| 157 | Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer Journal, 2021, 11, 117. | 2.8 | 6 |
| 158 | Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. American Journal of Blood Research, 2012, 2, 9-17. | 0.6 | 6 |
| 159 | Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603. | 2.3 | 6 |
| 160 | Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS8076-TPS8076. | 0.8 | 6 |
| 161 | Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. American Journal of Hematology, 2013, 88, 719-719. | 2.0 | 5 |
| 162 | Echocardiography and Survival in Light Chain Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007826. | 1.3 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis. American Journal of Hematology, 2019, 94, E194-E196. | 2.0 | 5 |
| 164 | Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. Blood, 2020, 136, 37-40. | 0.6 | 5 |
| 165 | Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 3480-3480. | 0.6 | 5 |
| 166 | Amyloidomics comes of age. Blood, 2012, 119, 1795-1796. | 0.6 | 4 |
| 167 | Microbiologically documented infections in patients undergoing highâ€dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transplant Infectious Disease, 2013, 15, 187-194. | 0.7 | 4 |
| 168 | Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. American Journal of Hematology, 2014, 89, 706-708. | 2.0 | 4 |
| 169 | Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2018, 53, 371-373. | 1.3 | 4 |
| 170 | Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood, 2018, 132, 755-757. | 0.6 | 4 |
| 171 | High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplantation, 2019, 54, 1304-1309. | 1.3 | 4 |
| 172 | Cardiac biomarkers and healthâ€related quality of life in patients with light chain (<scp>AL</scp>) amyloidosis. British Journal of Haematology, 2019, 185, 998-1001. | 1.2 | 4 |
| 173 | A pharmacistâ€™s review of the treatment of systemic light chain amyloidosis. Journal of Oncology Pharmacy Practice, 2021, 27, 187-198. | 0.5 | 4 |
| 174 | Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 425-426. | 0.2 | 4 |
| 175 | Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.. Blood, 2004, 104, 5226-5226. | 0.6 | 4 |
| 176 | Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation. Blood, 2012, 120, 2019-2019. | 0.6 | 4 |
| 177 | Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Medicine, 2022, 4, 100427. | 1.0 | 4 |
| 178 | Penile ulcers complicating systemic AL amyloidosis: a case report. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 203-204. | 1.4 | 3 |
| 179 | Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact. Blood, 2019, 134, 4758-4758. | 0.6 | 3 |
| 180 | Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis. Blood, 2010, 116, 3021-3021. | 0.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasoneâ€‰Â±â€‰daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730. | 2.0 | 3 |
| 182 | Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a â€˜melphalan recallâ€™ reaction. Bone Marrow Transplantation, 2010, 45, 21-24. | 1.3 | 2 |
| 183 | REDUCTION IN VENTRICULAR WALL THICKNESS FOLLOWING HIGH-DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANTATION FOR AL CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2010, 55, A36.E351. | 1.2 | 2 |
| 184 | Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 156-162. | 1.4 | 2 |
| 185 | Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. Journal of Vascular and Interventional Radiology, 2015, 26, 1578-1580. | 0.2 | 2 |
| 186 | High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplantation, 2018, 53, 1593-1595. | 1.3 | 2 |
| 187 | Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 113-114. | 1.4 | 2 |
| 188 | Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e460-e463. | 0.2 | 2 |
| 189 | The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study. Blood, 2019, 134, 4353-4353. | 0.6 | 2 |
| 190 | Durable Responses to Lenalidomide (RevlimidÂ®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.. Blood, 2007, 110, 192-192. | 0.6 | 2 |
| 191 | A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease. Blood, 2014, 124, 4767-4767. | 0.6 | 2 |
| 192 | Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis. Blood, 2015, 126, 3299-3299. | 0.6 | 2 |
| 193 | Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. American Journal of Medicine, 2022, 135, S30-S37. | 0.6 | 2 |
| 194 | A novel substitution of proline (P32L) destabilises Î²2-microglobulin inducing hereditary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-8. | 1.4 | 2 |
| 195 | Optimal dosing of high-dose melphalan prior to autologous hematopoietic stem cell transplantation in a patient with AL amyloidosis and a solitary kidney. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 86-88. | 0.6 | 1 |
| 196 | Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfusion and Apheresis Science, 2018, 57, 411-415. | 0.5 | 1 |
| 197 | Safety of autologous stem cell transplantation in patients with known Human Tâ€cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients. American Journal of Hematology, 2019, 94, E317-E319. | 2.0 | 1 |
| 198 | Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study. Blood, 2019, 134, 4578-4578. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.. Blood, 2009, 114, 4353-4353. | 0.6 | 1 |
| 200 | High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553. | 0.6 | 1 |
| 201 | Macroglossia â€“ Not Always AL Amyloidosis. Blood, 2010, 116, 5007-5007. | 0.6 | 1 |
| 202 | Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood, 2013, 122, 3328-3328. | 0.6 | 1 |
| 203 | The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood, 2015, 126, 5490-5490. | 0.6 | 1 |
| 204 | Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 4523-4523. | 0.6 | 1 |
| 205 | A phase II trial of lenalidomide for patients with AL amyloidosis. Journal of Clinical Oncology, 2006, 24, 7524-7524. | 0.8 | 1 |
| 206 | Treatment of Al Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126. | | 1 |
| 207 | AL (Immunoglobulin Light-Chain) Amyloidosis. , 2008, , 551-569. | | 1 |
| 208 | Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394. | 0.6 | 1 |
| 209 | Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT). Blood, 2011, 118, 2041-2041. | 0.6 | 1 |
| 210 | Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. Blood, 2011, 118, 2004-2004. | 0.6 | 1 |
| 211 | Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis. Blood, 2013, 122, 1991-1991. | 0.6 | 1 |
| 212 | Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, , . | 0.2 | 1 |
| 213 | Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplantation, 2015, 50, 868-869. | 1.3 | 0 |
| 214 | David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957â€“2015. Bone Marrow Transplantation, 2016, 51, 323-323. | 1.3 | 0 |
| 215 | A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurology, 2017, 74, 476. | 4.5 | 0 |
| 216 | Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Quantitative Serum Free Light-Chain Assay in the Diagnostic Evaluation of Al Amyloidosis. , 2004, , 90-92. | | 0 |
| 218 | Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2004, 104, 2393-2393. | 0.6 | 0 |
| 219 | Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.. Blood, 2005, 106, 4078-4078. | 0.6 | 0 |
| 220 | High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.. Blood, 2005, 106, 5476-5476. | 0.6 | 0 |
| 221 | Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.. Blood, 2005, 106, 1160-1160. | 0.6 | 0 |
| 222 | Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.. Blood, 2006, 108, 612-612. | 0.6 | 0 |
| 223 | Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.. Blood, 2007, 110, 2873-2873. | 0.6 | 0 |
| 224 | Localized AL Amyloidosis of the Breast: A Case Series.. Blood, 2009, 114, 4906-4906. | 0.6 | 0 |
| 225 | Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.. Blood, 2009, 114, 2318-2318. | 0.6 | 0 |
| 226 | Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.. Blood, 2009, 114, 4352-4352. | 0.6 | 0 |
| 227 | Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2009, 114, 1883-1883. | 0.6 | 0 |
| 228 | Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.. Blood, 2009, 114, 4356-4356. | 0.6 | 0 |
| 229 | Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis. Blood, 2010, 116, 3022-3022. | 0.6 | 0 |
| 230 | High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. Blood, 2011, 118, 2043-2043. | 0.6 | 0 |
| 231 | Melphalan, Lenalidomide and Dexamethasone Combination Therapy In Patients with AL Amyloidosis. Blood, 2011, 118, 2924-2924. | 0.6 | 0 |
| 232 | Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide. Blood, 2012, 120, 1873-1873. | 0.6 | 0 |
| 233 | Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial. Blood, 2012, 120, 4084-4084. | 0.6 | 0 |
| 234 | Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2013, 31, 8545-8545. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation. Blood, 2013, 122, 4728-4728. | 0.6 | 0 |
| 236 | Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study. Blood, 2014, 124, 3463-3463. | 0.6 | 0 |
| 237 | Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients. Blood, 2014, 124, 4750-4750. | 0.6 | 0 |
| 238 | Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio. Blood, 2015, 126, 2956-2956. | 0.6 | 0 |
| 239 | Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients. Blood, 2015, 126, 5499-5499. | 0.6 | 0 |
| 240 | A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation. Blood, 2015, 126, 5484-5484. | 0.6 | 0 |
| 241 | Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis. Blood, 2018, 132, 4616-4616. | 0.6 | 0 |
| 242 | The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades. Blood, 2018, 132, 5536-5536. | 0.6 | 0 |
| 243 | Successful transition from bortezomib subcutaneous to generic intravenous bortezomib: Cost savings initiative with global economic impact.. Journal of Clinical Oncology, 2020, 38, e19375-e19375. | 0.8 | 0 |
| 244 | Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab. Blood, 2021, 138, 2734-2734. | 0.6 | 0 |
| 245 | Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis. Bone Marrow Transplantation, 2021, , . | 1.3 | 0 |
| 246 | Beyond Survival in AL amyloidosis: Identifying and Satisfying Patientsâ€™ Needs. Hemato, 2022, 3, 38-46. | 0.2 | 0 |
| 247 | Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51. | 0.6 | 0 |
| 248 | Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments. Blood, 2020, 136, 38-39. | 0.6 | 0 |
| 249 | Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications. Blood, 2020, 136, 23-24. | 0.6 | 0 |
| 250 | Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Blood, 2020, 136, 4-5. | 0.6 | 0 |
| 251 | AL amyloidosis: who, what, when, why, and where. Oncology, 2012, 26, 164, 166, 169. | 0.4 | 0 |
| 252 | Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. British Journal of Haematology, 2022, , . | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer Journal, 2022, 12, . | 2.8 | 0 |